Glecaprevir 100 mg/Pibrentasvir 40 mg (Mavyret) is a combination medication used to treat chronic hepatitis C virus (HCV) infection in adults and pediatric patients. It is marketed under the brand name Mavyret and is composed of two direct-acting antiviral agents (DAAs): glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor). These agents work together to block different steps in the HCV replication cycle, ultimately leading to the elimination of the virus.

Here’s a detailed product description for Glecaprevir 100 mg/Pibrentasvir 40 mg (Mavyret):

Glecaprevir 100 mg/Pibrentasvir 40 mg (Mavyret)

Product Overview: Glecaprevir 100 mg/Pibrentasvir 40 mg (Mavyret) is a fixed-dose combination of glecaprevir and pibrentasvir, two direct-acting antiviral (DAA) medications used for the treatment of chronic hepatitis C (HCV) in adults and pediatric patients. Mavyret is effective for a wide range of HCV genotypes, offering a shorter treatment duration with a high cure rate. It works by inhibiting the enzymes necessary for the virus to replicate, helping to clear the infection and prevent liver damage.

Key Benefits:

• Pan-genotypic treatment for HCV, meaning it is effective against all major genotypes of the virus.
• Short treatment duration: Typically taken for 8 to 12 weeks, depending on the individual’s health condition.
• Offers high cure rates, often achieving a sustained virologic response (SVR) after treatment completion.
• No need for ribavirin or interferon, making it a more convenient and better-tolerated alternative.
• Oral treatment, taken once daily, simplifying the treatment regimen.

Indications:

• Treatment of chronic hepatitis C virus (HCV) infection in adults and pediatric patients (12 years and older) with genotype 1–6 HCV.
• Mavyret is approved for use in patients with compensated cirrhosis and those with HIV/HCV co-infection.

Dosage:

• The usual dose is one tablet (Glecaprevir 100 mg/Pibrentasvir 40 mg) taken once daily with food.
• The treatment duration is generally 8 weeks for most patients without cirrhosis and 12 weeks for patients with cirrhosis or other complications. Your healthcare provider will determine the correct duration based on your condition.

Precautions:

• Liver function: Regular monitoring of liver enzymes is recommended during treatment, especially for those with liver cirrhosis.
• Drug interactions: Mavyret can interact with other medications, so it is important to inform your healthcare provider of any other drugs you are taking.
• Not recommended for use in patients with severe liver problems or decompensated cirrhosis.
• Mavyret is not recommended during pregnancy and should only be used under a healthcare provider’s supervision if absolutely necessary.

Common Side Effects:

• Headache
• Fatigue
• Nausea
• Diarrhea
• Insomnia
• Loss of appetite

Packaging:

• Mavyret (Glecaprevir 100 mg/Pibrentasvir 40 mg) tablets are conveniently packaged in a [insert packaging type] for easy administration.

Important Notes:

• Take with food: It is important to take Mavyret with food to ensure the medication is absorbed properly.
• Adherence to dosage: Skipping doses may reduce the effectiveness of the treatment. If you miss a dose, take it as soon as you remember unless it’s close to your next dose.
• Store the medication in a cool, dry place away from direct sunlight and out of reach of children.